The Olympic medallist's testing startup just landed seed funding for a US launch and a new biological age score, but rival at-home age tests still disagree by over a decade for the same person.
A seed round for the testing era
Stride, a Norwich based preventative health startup, has raised £4.6 million in seed funding, the company and multiple UK outlets confirmed on October 14, 2026. The round brings in Arāya Ventures, Better Ventures, Morgan Stanley's Inclusive & Sustainable Ventures arm, an unnamed investor from the a16z Scout Fund and a group of angels, with Innovate UK layering grant funding on top, according to BusinessCloud and The Cap Table.
The company was founded in 2024 by Andrew Steele, who won bronze in the 4x400m relay at the Beijing 2008 Olympics before moving into consumer genetic testing. "For most of my life, I've been obsessed with understanding what makes people perform at their best," he said, per Tech Funding News. "Preventative health can sometimes sound boring or worthy, when actually it could be one of the most transformative opportunities of our generation."
That is a reasonable claim about prevention in general. It is a bigger claim once it is attached to a specific product: a membership that tests your DNA, blood and gut, then compresses the results into one number called your biological age.
What the money actually buys
The plan is to take the Stride One membership beyond the UK and into the US before the end of 2026, and to build a new "StrideAge" test alongside an AI health copilot, each backed by a separate Innovate UK grant: one for multiomic biological age research, one for combining lab results with wearable and health record data.
Stride's own site shows what is live today: a DNA and methylation test analysing 164 genetic variants, a gut microbiome panel covering 406 markers priced at $377.30, and a service that reprocesses existing 23andMe data into a methylation report. The flagship StrideOne membership is not yet open to new customers; the site currently reads "StrideOne is coming" with a waitlist, which fits a company mid relaunch around a funding announcement rather than one with years of customer data behind it.
“Preventative health can sometimes sound boring or worthy, when actually it could be one of the most transformative opportunities of our generation.”
The number doing the heavy lifting
StrideAge, per Tech Funding News, is built from nine blood biomarkers. That detail matters more than it looks. The best studied nine marker blood age formula in the scientific literature is Levine's PhenoAge: albumin, creatinine, glucose, CRP, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase and white blood cell count, validated against mortality in an independent sample of over 11,000 people. The catch sits in that same validation paper: phenotypic age correlated with chronological age at r equals 0.94. A score tied that tightly to your birth year is not telling you much you did not already know, whatever formula Stride ends up running.
Formulas also disagree with each other in ways that matter for a subscription priced in the hundreds of pounds a year. One head to head comparison sent the same person's blood and saliva to seven different biological age providers on the same day and got results from 24.9 to 38, a 13.1 year spread, against a real age of 30.4. Our own look at whether biological age tests actually work found the same pattern: the scientists who built the clocks say they are not designed to tell one individual anything reliable, and no trial has shown that pushing your number down adds healthy years. Stride has not published independent validation data for StrideAge, and its own terms describe its DNA, methylation and microbiome tests as "educational, not diagnostic, and not intended to monitor, predict or prevent any disease," language that sits awkwardly next to marketing about the test showing you exactly what changed.
What is genuinely useful here
None of this makes Stride a scam. Testing fasting glucose, CRP, kidney function and a handful of other biomarkers on a schedule, with a human coach attached, beats doing nothing, and some of what Stride sells overlaps with bloodwork any GP would order. Innovate UK does not hand out grant money freely, and Morgan Stanley's inclusive ventures arm backing the round says something real about the deal, even if it says nothing about the science behind a single age score. Stride has also built paid relationships with hospitality partners Triple Bond and LongLane to put its testing in front of wellness travellers, a sign of commercial traction beyond the funding headline.
The gap is specific: the single biological age number is the part of the product with the thinnest evidence behind it, and the part most likely to end up in an advert. That tension runs through the wider category Stride competes in, which is why it is worth tracking against our broader coverage of funding and acquisitions in the wellness industry.
“Healthcare has traditionally been built around treating problems once they appear.”
Our take
Stride raised real money from credible investors to do something real: regular, coached testing of biomarkers that mostly have evidence behind them individually. The biological age number bolted on top is doing marketing work, not medical work, and Stride's own fine print says so. If you join, read the underlying blood panel and treat the single score as entertainment, not a diagnosis.
Health Trend Wire holds no position in Stride and was not paid for this article. This is general information, not medical or financial advice.
Frequently asked questions
How much funding did Stride raise and when?
Stride, a UK preventative health startup, raised £4.6 million in seed funding announced on 14 October 2026. Investors included Arāya Ventures, Better Ventures, Morgan Stanley's inclusive ventures arm, an a16z Scout Fund investor and angel backers, with Innovate UK adding grant funding for two research projects.
What does Stride's testing membership actually include?
Stride combines a DNA and methylation test, a gut microbiome panel covering hundreds of markers, and a blood panel, alongside quarterly consultations and its own supplements. The company plans to add a new 'StrideAge' biological age score and launch the membership in the US before the end of 2026.
Are at-home biological age tests accurate?
Not reliably for one person. A comparison that tested the same person's blood and saliva with seven different providers on the same day got results ranging from 24.9 to 38 years old, a 13.1-year spread, against a real chronological age of 30.4.
What biomarkers go into a biological age score like StrideAge?
Stride's score is reportedly built from nine blood biomarkers. The best-studied nine-marker formula, Levine's PhenoAge, uses albumin, creatinine, glucose, CRP and five other markers, and in validation testing it correlated with chronological age at r=0.94, meaning it mostly tracks your birth year.
Does Stride's fine print match its marketing claims?
Not entirely. Stride's own terms describe its DNA, methylation and microbiome tests as educational, not diagnostic, and say they are not intended to monitor, predict or prevent disease, even as its marketing describes the tests showing exactly what changed in your health.
Who founded Stride and what is his background?
Stride was founded in 2024 by Andrew Steele, who won Olympic bronze in the 4x400m relay at Beijing 2008 before moving into consumer genetic testing, and who now pitches preventative health as one of the biggest opportunities of this generation.
Sources
- 2
Olympic medallist raises £4.6m for HealthTech Stride, BusinessCloud
- 5
Biological age test comparison, Outliyr